Disclosures for "ReNeu: A Pivotal Phase 2b Trial of Mirdametinib in Children and Adults With Neurofibromatosis Type 1 (NF1)-Associated Symptomatic Plexiform Neurofibroma (PN)"
-
The institution of Dr. Shuhaiber has received research support from SPRINGWORKS . The institution of Dr. Shuhaiber has received research support from RECURSION . The institution of Dr. Shuhaiber has received research support from AstraZeneca. The institution of Dr. Shuhaiber has received research support from CTF. The institution of Dr. Shuhaiber has received research support from NFLECTION .
-
Dr. Moertel has received personal compensation for serving as an employee of OX2 Therapeutics. Dr. Moertel has received personal compensation for serving as an employee of Alexion . Dr. Moertel has received personal compensation for serving as an employee of Springworks. Dr. Moertel has stock in OX2 Therapeutics. Dr. Moertel has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Hirbe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SpringWorks Therapeutic. Dr. Hirbe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Hirbe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aadi Subsidiary Inc. The institution of Dr. Hirbe has received research support from Tango. Dr. Hirbe has received intellectual property interests from a discovery or technology relating to health care.
-
The institution of David Viskochil, MD, PhD has received research support from Astellas. The institution of David Viskochil, MD, PhD has received research support from Takeda. The institution of David Viskochil, MD, PhD has received research support from Springworks. The institution of David Viskochil, MD, PhD has received research support from NFlection.
-
The institution of Dr. Sidhu has received research support from SpringWorks Therapeutics.
-
Kevin Bielamowicz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion Pharmaceuticals. Kevin Bielamowicz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Springworks Therapeutics. Kevin Bielamowicz has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion Pharmaceuticals.
-
Dr. Weber has received personal compensation for serving as an employee of SpringWorks Therapeutics. Dr. Weber has stock in SpringWorks Therapeutics.
-
Dr. Lokku has nothing to disclose.
-
Dr. Smith has received personal compensation for serving as an employee of SpringWorks Therapeutics Inc. Dr. Smith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for SpringWorks Therapeutics. Dr. Smith has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Lifordi Immunotherapeutics.
-
Dr. Weintraub has nothing to disclose.
-
The institution of Dr. McNall-Knapp has received research support from SpringWorks. The institution of Dr. McNall-Knapp has received research support from Alexion. The institution of Dr. McNall-Knapp has received research support from Pfizer.
-
Dr. HAJJAR has nothing to disclose.
-
Prof. Foreman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Georgia University.
-
Author has nothing to disclose
-
Dr. babovic-vuksanovic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZeneca/Alexion. Dr. babovic-vuksanovic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SpringWorks. Dr. babovic-vuksanovic has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. babovic-vuksanovic has received research support from SprinWorks. Dr. babovic-vuksanovic has received publishing royalties from a publication relating to health care. Dr. babovic-vuksanovic has received personal compensation in the range of $500-$4,999 for serving as a USMLE items review with NBME.